Comorbid Patients with Multiple Myeloma: Considering All the Facts in Treatment Selection
Release Date: November 19, 2018
Expiration Date: November 19, 2019
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
Notice: Participants who attended the live webinar and received credit are not eligible to receive additional CME/CE credit from this online activity.
Mastering the most up-to-date treatment in practice today requires the ability to recall not only available and emerging treatment options, but also strategies and response assessment approaches for high-risk patients, which includes treatment options for patients with comorbidities. Most importantly, practitioners must then safely and effectively translate this knowledge into patient-specific management plans, factoring in the patients’ comorbidities, age, and previous treatment history. This activity is designed to provide an evidenced-based overview addressing how community practitioners may navigate the ever-increasing number of highly effective options for approaching newly diagnosed multiple myeloma in patients who present with – or develop – comorbidities associated with their disease.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Identify how comorbidities in patients with multiple myeloma can affect treatment choices
- Summarize guidelines for standard induction regimens for newly diagnosed MM patients and how they can be affected by comorbidities
- Determine the best treatment option for patients with multiple myeloma and comorbidities
Comorbid Patients with Multiple Myeloma: Considering All the Facts in Treatment Selection –Sergio A. Giralt, MD, FACP, and Beth Faiman, PhD, CNP, MSN, APRN-BC, AOCN®
Instructions for Participation and Credit
This activity is eligible for credit through November 19, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Sergio A. Giralt, MD, FACP
Melvin Berlin Family Chair in Myeloma Research
Professor of Medicine
Weill Cornell Medical College
Chief Attending Physician
Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela. He completed his residency at Good Samaritan Hospital and his fellowship at The University of Texas MD Anderson Cancer Center. Dr. Giralt is Professor of Medicine at Weill Cornell Medical College and the Chief Attending Physician of the Adult Bone Marrow Transplant Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York City. In addition, he is the Melvin Berlin Family Chair in Myeloma Research.
Dr. Giralt is board certified in internal medicine with subspecialties in medical oncology and hematology. He is an active member of the American Medical Association, American College of Physicians, American Society of Hematology, American Society of Clinical Oncology, North American Society of Blood and Bone Marrow Transplantation (ASBMT), International Society of Hematotherapy and Graft Engineering, International Society of Haematology, and the Gerontological Society of America. Dr. Giralt previously served as chairperson on the executive board of the Center for International Blood and Marrow Transplant Research, the steering committee of the Blood and Marrow Transplant Clinical Trials Network, and is past president of ASBMT.
Dr. Giralt’s clinical and research activities include stem cell transplantation for patients with blood disorders and improving treatments for older patients who have acute and chronic leukemia. He has published and presented extensively on these topics. Additionally, Dr. Giralt has served as the principal investigator for a number of clinical trials that examine new treatment approaches for multiple myeloma and other blood cancers that aim to reduce symptom burden and improve treatment tolerability.
Beth Faiman, PhD, CNP, MSN, APRN-BC, AOCN®
Cleveland Clinic Taussig Cancer Institute
Dr. Beth Faiman received her bachelor of science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio. She received a master of science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio, and a PhD in Clinical Research and Nursing from Case Western Reserve University. Dr. Faiman holds an advanced oncology nurse certification through Oncology Nursing Certification Corporation (ONCC). She is an Adult Nurse Practitioner in the Department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic in Cleveland, Ohio, and adjunct faculty at Ursuline College, Case Western Reserve University and Kent State University.
Dr. Faiman is an active author, presenter, and educator on the topic of multiple myeloma, chronic lymphocytic leukemia, plasma cell dyscrasias, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is an appointed delegate on the International Myeloma Foundation Nurse Leadership Board. Dr. Faiman is currently editor-in-chief of The Oncology Nurse APN/PA, and is on the editorial board of ASH Clinical News, among others. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of multiple myeloma, treatment adherence, pain, palliation, and cancer symptom management. Dr. Faiman received the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University, and was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-045-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-045-090
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sergio Giralt has received honoraria related to formal advisory activities and as a consultant from Amgen Inc., Jazz Pharmaceuticals plc, Kite Pharma, Novartis AG, and Sanofi.
Dr. Beth Faiman has received honoraria related to speakers’ bureau activities and as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.